# Guangdong Rongtai Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/guangdong-rongtai-pharmaceutical-co

- Industry: Healthcare
- Headquarters: Guangzhou, China
- Website: www.khpharm.com
- Total disclosed funding: $46M
- Latest round: Series A (Jul 20, 2021)
- Investors on record: 4

## About

Established in 2004 and based in Guangzhou, China, Guangdong Rongtai Pharmaceutical Co.,Ltd. is a service provider that focuses on comprehensive services of Internet marketing and supply chain management for pharmaceutical companies. In 2020, the company changed its name from Guangdong Kanghong Medicine Co.,Ltd. to Guangdong Rongtai Pharmaceutical Co.,Ltd..

The company engages in providing medical delivery services. The drugs it provides include azelastine hydrochloride nasal spray, alogliptin benzoate tablets, entecavir tablets and indapamide sustained-release capsules, etc. The company markets products through e-commerce and new retail. The company engages in B2B and B2C.

## Funding rounds

- Series A, Jul 20, 2021, $46M — Oriental Fortune Capital, Hidea Investment, Shenzhen Capital Real Estate Fund
- Angel, Feb 9, 2021 — Hollyhigh International Capital

## Investors

- Hollyhigh International Capital (https://capitalatlas.ai/funds/hollyhigh-international-capital) — Angel
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A
- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A